Literature DB >> 20125160

Oncolytic viruses: an approved product on the horizon?

John Bell.   

Abstract

Mesh：

Year:  2010        PMID： 20125160      PMCID： PMC2839306          DOI： 10.1038/mt.2009.314

Source DB:  PubMed          Journal:  Mol Ther        ISSN： 1525-0016            Impact factor:   11.454


× No keyword cloud information.
  8 in total

Review 1.  Cell-based delivery of oncolytic viruses: a new strategic alliance for a biological strike against cancer.

Authors:  Anthony T Power; John C Bell
Journal:  Mol Ther       Date:  2007-01-30       Impact factor: 11.454

2.  Rescue and propagation of fully retargeted oncolytic measles viruses.

Authors:  Takafumi Nakamura; Kah-Whye Peng; Mary Harvey; Suzanne Greiner; Ian A J Lorimer; Charles D James; Stephen J Russell
Journal:  Nat Biotechnol       Date:  2005-01-30       Impact factor: 54.908

3.  Synergistic effects of oncolytic reovirus and cisplatin chemotherapy in murine malignant melanoma.

Authors:  Hardev S Pandha; Lucy Heinemann; Guy R Simpson; Alan Melcher; Robin Prestwich; Fiona Errington; Matt Coffey; Kevin J Harrington; Richard Morgan
Journal:  Clin Cancer Res       Date:  2009-09-22       Impact factor: 12.531

4.  A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer.

Authors:  Laura Vidal; Hardev S Pandha; Timothy A Yap; Christine L White; Katie Twigger; Richard G Vile; Alan Melcher; Matt Coffey; Kevin J Harrington; Johann S DeBono
Journal:  Clin Cancer Res       Date:  2008-11-01       Impact factor: 12.531

5.  Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma.

Authors:  Neil N Senzer; Howard L Kaufman; Thomas Amatruda; Mike Nemunaitis; Tony Reid; Gregory Daniels; Rene Gonzalez; John Glaspy; Eric Whitman; Kevin Harrington; Howard Goldsweig; Tracey Marshall; Colin Love; Robert Coffin; John J Nemunaitis
Journal:  J Clin Oncol       Date:  2009-11-02       Impact factor: 44.544

6.  Human cancer cells have specifically lost the ability to induce the synergistic state caused by tumor necrosis factor plus interferon-beta.

Authors:  Eric Bartee; Grant McFadden
Journal:  Cytokine       Date:  2009-07-28       Impact factor: 3.861

7.  Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial.

Authors:  Byeong-Ho Park; Taeho Hwang; Ta-Chiang Liu; Daniel Y Sze; Jae-Seok Kim; Hyuk-Chan Kwon; Sung Yong Oh; Sang-Young Han; Jin-Han Yoon; Sook-Hee Hong; Anne Moon; Kelly Speth; Chohee Park; Young-Joo Ahn; Manijeh Daneshmand; Byung Geon Rhee; Herbert M Pinedo; John C Bell; David H Kirn
Journal:  Lancet Oncol       Date:  2008-05-19       Impact factor: 41.316

Review 8.  An overview of small-molecule inhibitors of VEGFR signaling.

Authors:  S Percy Ivy; Jeannette Y Wick; Bennett M Kaufman
Journal:  Nat Rev Clin Oncol       Date:  2009-09-08       Impact factor: 66.675
  8 in total
  9 in total

1.  Intravenously injected Newcastle disease virus in non-human primates is safe to use for oncolytic virotherapy.

Authors:  P R A Buijs; G van Amerongen; S van Nieuwkoop; T M Bestebroer; P R W A van Run; T Kuiken; R A M Fouchier; C H J van Eijck; B G van den Hoogen
Journal:  Cancer Gene Ther       Date:  2014-09-26       Impact factor: 5.987

2.  Oncogenic Ras inhibits IRF1 to promote viral oncolysis.

Authors:  Y Komatsu; S L Christian; N Ho; T Pongnopparat; M Licursi; K Hirasawa
Journal:  Oncogene       Date:  2014-10-27       Impact factor: 9.867

3.  Vesicular stomatitis virus oncolytic treatment interferes with tumor-associated dendritic cell functions and abrogates tumor antigen presentation.

Authors:  Simon Leveille; Marie-Line Goulet; Brian D Lichty; John Hiscott
Journal:  J Virol       Date:  2011-09-14       Impact factor: 5.103

4.  Different responses of human pancreatic adenocarcinoma cell lines to oncolytic Newcastle disease virus infection.

Authors:  P R A Buijs; C H J van Eijck; L J Hofland; R A M Fouchier; B G van den Hoogen
Journal:  Cancer Gene Ther       Date:  2014-01-03       Impact factor: 5.987

Review 5.  Reovirus: a targeted therapeutic--progress and potential.

Authors:  Radhashree Maitra; Mohammad H Ghalib; Sanjay Goel
Journal:  Mol Cancer Res       Date:  2012-10-04       Impact factor: 5.852

6.  Paramyxovirus entry and targeted vectors for cancer therapy.

Authors:  Roberto Cattaneo
Journal:  PLoS Pathog       Date:  2010-06-24       Impact factor: 6.823

Review 7.  Oncolytic viruses in the treatment of cancer: a review of current strategies.

Authors:  Md Zeyaullah; Mohan Patro; Irfan Ahmad; Kawthar Ibraheem; P Sultan; M Nehal; Arif Ali
Journal:  Pathol Oncol Res       Date:  2012-06-20       Impact factor: 2.874

8.  Stabilisation of p53 enhances reovirus-induced apoptosis and virus spread through p53-dependent NF-κB activation.

Authors:  D Pan; L-Z Pan; R Hill; P Marcato; M Shmulevitz; L T Vassilev; P W K Lee
Journal:  Br J Cancer       Date:  2011-08-23       Impact factor: 7.640

9.  Virotherapy, gene transfer and immunostimulatory monoclonal antibodies.

Authors:  José I Quetglas; Liza B John; Michael H Kershaw; Luis Alvarez-Vallina; Ignacio Melero; Phillip K Darcy; Cristian Smerdou
Journal:  Oncoimmunology       Date:  2012-11-01       Impact factor: 8.110
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.